Citius Pharmaceuticals, Inc. (CTXR)

Pharmaceutical Preparations · market cap $16M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-22 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Citius Pharmaceuticals (CTXR) is a micro-cap pharmaceutical company with a $14M market cap and 23 employees, focused on hemorrhoid treatments. Its lead asset Monad 1 is in Phase 2, alongside a hydrocortisone acetate/lidocaine hydrochloride combination also in Phase 2 for the same indication. The company carries $295.4M in net debt against $4.6M in cash, implying roughly one month of runway.

The catalyst path

2026-12-22 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Monad 1	Phase 2	Hemorrhoids

Price & technical context

3-month

-17.6%

6-month

-13.8%

12-month

-58.8%

52-wk range

$0.37–$1.44

vs 50-day MA

+5.0%

vs 200-day MA

-14.0%

Realized vol

109.4%

Max drawdown

-96.9%

Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CTXR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.